Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

Katie Adams is a senior reporter for MedCity News covering providers and healthcare technology. Previously, she worked as a healthcare technology editor at Becker’s Hospital Review. Her journalism ...

Tens of thousands of Kaiser Permanente workers in California and Hawaii have gone on strike, demanding safer staffing levels ...

Stephanie Baum is the Director of Special Projects for MedCityNews. She graduated from Franklin & Marshall College in Pennsylvania and has worked across radio, print and video. She's worked for Dow ...

From left to right: Moderator Michael Kalishman, chief venture officer, Sentara Health; Nick Culbertson, managing director, Techstars; Dr. Ngoc-Anh Nguyen, vice chair of research, Houston Methodist ...

Kailera Therapeutics executives say their lead drug candidate could become best in a category of obesity drugs currently led by a blockbuster Eli Lilly product, and the biotech has secured $600 ...

Insurers are cutting coverage for costly GLP-1 weight loss drugs, sparking backlash from advocates who say they're vital for ...

Interoperability doesn’t start with a 9-1-1 call. It begins with a commitment to data quality, documentation integrity, and adherence to national standards across the system. For EMS, this means ...

Bristol Myers Squibb is securing an opportunity to compete in the next generation of cell therapies through the $1.5 billion acquisition of Orbital Therapeutics, a startup with a lead program nearing ...

The U.S. has a lower life expectancy and higher rate of premature death than any other wealthy country. This is despite the fact that we spend nearly twice as much per capita on healthcare. Exorbitant ...

Oral Genome is collaborating with Harmony Health and United Concordia Dental to pilot its salivary testing technology. Three Pennsylvania dental organizations have launched a pilot using Oral Genome’s ...